Sino Biopharm Wins China Approval for New Alveolar Soft Part Sarcoma Therapy

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.

Sino Biopharmaceutical announced that its subsidiary’s drugs Benmelstobart, an anti-PD-L1 monoclonal antibody, and Anlotinib, a multi-targeted tyrosine kinase inhibitor, have been approved in China as a combination therapy for advanced or unresectable alveolar soft part sarcoma. This marks the fourth approved indication for the combo and the fifth and eleventh indications for Benmelstobart and Anlotinib respectively, underscoring the company’s growing oncology franchise.

The approval is backed by strong clinical data showing a 72.41% objective response rate and a 10.34% complete response rate, with no new safety signals and median progression-free survival not yet reached at 24.9 months of follow-up. Given ASPS is a rare, highly metastatic cancer with poor response to conventional therapies and limited treatment options, this new indication, aligned with guideline recommendations for Anlotinib, strengthens Sino Biopharmaceutical’s position in high-need oncology niches and offers a significant new option for patients in China.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on the research, development, manufacturing and commercialization of innovative medicines. Through subsidiaries such as Chia Tai Tianqing Pharmaceutical Group, it develops category 1 innovative drugs, with a portfolio spanning oncology and other therapeutic areas targeting the China healthcare market.

YTD Price Performance: -0.16%

Average Trading Volume: 69,721,589

Technical Sentiment Signal: Buy

Current Market Cap: HK$110.3B

See more data about 1177 stock on TipRanks’ Stock Analysis page.